The BC Cancer REB is UBC-affiliated and complies with many of their policies, procedures, and guidelines (see UBC Policies & SOPs) and aligns with the UBC Clinical Research Ethics Board (CREB) with some institution-specific differences.
All persons who are involved in research at BC Cancer are responsible for familiarizing themselves with these policies, procedures, and guidelines, as well as ensuring compliance with all relevant and applicable regulations, such as TCPS2 2022 and FDA Regulations.
Below document outlines the principles/procedures relating to the ethical review and conduct of chart reviews, including guidance on obtaining consent, waiver of consent, and post-approval activities:
BC Cancer REB Guidance for Chart Reviews.August 2019.pdf
Combined Phase I/II Clinical Trials:
In absence of Phase I results, proposals of combined Phase I/II clinical trials can raise ethical concerns related to participant safety. However, recognizing potential benefits of such trial designs, below guideline was developed to protect research participants and to assist on framing the REB submissions for timely review:
BCC REB Guidelines for Combined Phase I and II Clinical Trials. May 2018.pdf
In collaboration with the Continuous Improvement and Performance Team, this guidance was developed to assist in determining if your project is considered research:
|9 September 2022|
|All documents for all research studies are expected to be presented in a language understandable to the participant. See guidance below for resources, references, definitions and FAQs:|
BC Cancer REB Guidance on the Use of Interpreters and Translated Documents.December 2019.pdf
Hints and Tips document for considerations on the applicability of the above guidance to your study:
BC Cancer REB Hints and Tips on the Use of Interpreters and Translated Documents.February 2020.pdf
The document describes the
scope, definition and the
review process of multi-jurisdictional research involving human participants within British Columbia:
Guidance for Ethical Review of BC Cancer Multi-Jurisdictional Research.pdf
Upon request, Health Canada's SAP may allow for compassionate access to a drug that is
unavailable for sale in Canada. The determination is made on a patient-by-patient bases, with limited access to provision to patients with serious or life-threatening conditions.
REB submissions of SAP requests are
not required; all regulatory requirements should be dealt directly with Health Canada.
HC Special Access Program and REB Review.pdf (PDF)
BC Cancer REB Student Research Guidance.pdf (PDF)
BC Cancer REB Student Research Flow Chart.pdf
UBC Notice to Researchers Adding Students and Adding Funding Oct 2017.pdf (PDF)
NOTE: A student researcher cannot be a Principal Investigator on a BC Cancer research study. Please see guidance below for information on qualifications to be a PI on a study.
|BC Cancer REB deems that the use of third-party vendor search companies is not appropriate within the Canadian clinical trials context. See letter for more information:|
Letter - Third Party Search Companies.2019.pdf
|26 February 2019|
BC Cancer Research Ethics - Who Can Be a Principal Investigator on a BC Cancer research project.pdf||
9 July 2020
- Clinical Research Ethics Board (CREB)
- Behavioural Research Ethics Board (BREB)